Joint Formulary & PAD

Lorazepam - Anxiety

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :
Important

For short term use only

Do not offer a benzodiazepine for the treatment of any anxiety disorder in primary or secondary care except as a short-term measure (2-4 weeks) during crisis. Follow the advice in the BNF on the use of a benzodiazepine in this context. 

Avoid in the elderly

Beware of MHRA advice on coprescribing of benzodiazepines and opioid and risk of death

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Lorazepam
Indication :
Anxiety
Group Name :
Keywords :
benzodiazepines, anxiolytics
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

This drug has been agreed as appropriate for initiation in Primary Care and/or continued in Primary Care following a recommendation from specialists in other health care sectors. Following consideration by the PCN, it has been assigned a GREEN traffic light status

Other Indications

Below are listed other indications that Lorazepam is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Anxiety.